UK markets closed

CVAC Jan 2023 145.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.57000.0000 (0.00%)
At close: 04:30PM EDT
Full screen
Previous close0.5700
Open0.5700
Bid0.0000
Ask2.5000
Strike145.00
Expiry date2023-01-20
Day's range0.5700 - 0.5700
Contract rangeN/A
Volume2
Open interest2
  • Simply Wall St.

    CureVac (NASDAQ:CVAC) Is In A Good Position To Deliver On Growth Plans

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

  • EQS Group

    CureVac Announces Financial Results for the First Quarter of 2022 and Provides Business Update

    Issuer: CureVac / Key word(s): Quarter Results25.05.2022 / 13:05 The issuer is solely responsible for the content of this announcement.CureVac Announces Financial Results for the First Quarter of 2022 and Provides Business Update Progressing broad vaccine development program in collaboration with GSK, with second-generation candidates in Phase 1 clinical trials for COVID-19 and influenza CureVac eligible to a €10 million milestone payment from GSK for the initiation of the influenza clinical tri

  • EQS Group

    CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development

    Issuer: CureVac / Key word(s): Alliance25.05.2022 / 13:00 The issuer is solely responsible for the content of this announcement.CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development CureVac is broadening its foundation in oncology, leveraging recent progress with its second-generation mRNA backbone The partnership combines CureVac’s mRNA technology with myNEO’s platform for the discovery and selection of tumor antigens predicted to elicit strong